ArticleTranslational pediatrics2025
Comprehensive analysis of disulfidoptosis-related genes reveals molecular heterogeneity and key regulators in retinoblastoma progression.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Disulfidoptosis, a newly recognised form of cell death, has been studied in many cancers but not in retinoblastoma. Therefore, this study aimed to investigate the role of disulfidoptosis-related genes (DRGs) in retinoblastoma. Methods: Three retinoblastoma datasets (GSE208143, GSE97508, and GSE24673) were obtained from the Gene Expression Omnibus database. Differentially expressed DRGs (DE-DRGs) in retinoblastoma were identified, and key genes were screened using machine learning algorithms. Consensus cluster analysis was applied to identify the disulfidoptosis-based molecular subtypes. The pathways and immune characteristics of the subtypes were examined via gene set variation analysis, single-sample gene set enrichment analysis, and ESTIMATE. The expression of key genes was validated in retinoblastoma cells, and their roles were explored through functional experiments. Results: Compared with controls, the disulfidoptosis score was significantly lower (P<0.05) in retinoblastoma, and eight DE-DRGs were identified, suggesting the potential involvement disulfidoptosis in retinoblastoma. Consensus clustering revealed two molecular subtypes (C1 and C2). The C2 subtype exhibited multiple activated oncogenic pathways associated with tumourigenesis, lower infiltration levels of immune cells, lower immune and stromal scores, and reduced immune checkpoint expression. Least absolute shrinkage and selection operator and support vector machine-recursive feature elimination algorithms identified two key down-regulated genes-EPAS1 and SLC7A11-in retinoblastoma. The expression of EPAS1 and SLC7A11 was significantly correlated with oxidative phosphorylation and immune cell infiltration levels. EPAS1 overexpression significantly inhibited the viability, migration, and invasion of retinoblastoma cells and induced their apoptosis (P<0.05). Furthermore, EPAS1 overexpression significantly increased the relative nicotinamide adenine dinucleotide phosphate (NADP)+/reduced NADP (NADPH) ratio in retinoblastoma cells (P<0.05). Conclusions: This study highlights the involvement of DRGs in retinoblastoma progression and molecular subtype heterogeneity. EPAS1 and SLC7A11 may serve as key targets for the diagnosis and treatment of retinoblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.